BioPharmSignal logoBioPharmSignal

Biotech News

Apellis Pharmaceuticals Reports Fourth Quarter and Full Year 2025 Financial Results

Apellis Pharmaceuticals (APLS)Apellis PharmaceuticalsEarnings

Full-year 2025 net product revenues of $689 million SYFOVRE ® (pegcetacoplan injection) full year 2025 net product revenue of $587 million EMPAVELI ® (pegcetacoplan) full year 2025 net product revenue of $102 million Regulatory submission for SYFOVRE prefilled syringe planned for the first half of

Related news

XFORX4 Pharmaceuticals2026-08-06 20:15 EST

X4 Pharmaceuticals Reports Second Quarter 2026 Financial Results and Provides Corporate Update

CRNXCrinetics Pharmaceuticals2026-08-03 20:05 EST

Crinetics Pharmaceuticals Reports Second Quarter 2026 Financial Results and Provides Business Update

CRNXCrinetics Pharmaceuticals2026-06-30 20:05 EST

Crinetics Pharmaceuticals to Report Second Quarter 2026 Financial Results on August 4, 2026

IMVTImmunovant2026-05-20 11:00 EST

Immunovant Provides Corporate Updates and Reports Financial Results for the Fourth Quarter and Fiscal Year Ended March 31, 2026

GPCRStructure Therapeutics2026-08-06 20:05 EST

Structure Therapeutics Reports Second Quarter 2026 Financial Results and Recent Highlights

CLDXCelldex Therapeutics2026-08-06 20:01 EST

Celldex Reports Second Quarter Financial Results and Provides Corporate Update

AVTXAvalo Therapeutics2026-08-06 11:00 EST

Avalo Therapeutics Reports Second Quarter 2026 Financial Results and Recent Business Updates

IMVTImmunovant2026-08-06 11:00 EST

Immunovant Provides Corporate Updates and Reports Financial Results for the Quarter Ended June 30, 2026

ARWRArrowhead Pharmaceuticals2026-08-04 20:01 EST

Arrowhead Pharmaceuticals Reports Fiscal 2026 Third Quarter Results

KRYSKrystal Biotech2026-08-03 11:00 EST

Krystal Biotech Announces Second Quarter 2026 Financial and Operating Results

View all latest news

Apellis Pharmaceuticals

Complement C3 Biology Apellis Pharmaceuticals develops medicines that inhibit complement protein C3, a central control point in the complement cascade. Its portfolio applies the same core biology to retinal, hematologic and renal diseases. SYFOVRE SYFOVRE is an intravitreal pegcetacoplan therapy and the first approved treatment for...

Recent company news

APLSApellis Pharmaceuticals2026-03-31 10:59 EST

Biogen to Acquire Apellis, Enhancing the Company’s Growth Portfolio in Immunology and Rare Disease, Bolstering Growth Outlook and Accelerating Expansion into Nephrology

APLSApellis Pharmaceuticals2026-03-02 12:00 EST

Apellis Announces Mikael Dolsten, M.D., Ph.D., to Join Board of Directors

APLSApellis Pharmaceuticals2026-02-24 12:05 EST

Apellis Pharmaceuticals Reports Fourth Quarter and Full Year 2025 Financial Results

APLSApellis Pharmaceuticals2026-02-23 12:00 EST

Apellis Pharmaceuticals to Present at the TD Cowen 46th Annual Health Care Conference

APLSApellis Pharmaceuticals2026-02-19 12:00 EST

Apellis Announces Eight Oral Presentations at the 49th Macula Society Annual Meeting

Stock data

Close
41.03 USD
Market cap
5.25B USD
Exchange
NASDAQ
Sector
Biopharma
Location
United States